Skip to main content
SpringerLink
Log in

PET in T-Cell Lymphoma

  • T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18FDG) uptake varies among different subtypes of lymphoma, a disparity that can be explained by the differences in histology, proliferation of tumor cells, and the ratio of viable tumor and reactive cells in the environment. These observations are based on investigation of B-cell lymphomas. Positron emission tomography (PET)/computed tomography (CT) was found to be useful both at staging and at measuring the therapeutic outcome after two to three cycles of chemotherapy (interim PET/CT). Several meta-analyses have confirmed the role of PET in evaluating the viability of the residual tumor mass after treatment. 18FDG-PET has been proved to have an excellent negative predictive value. Conversely, only a few studies have investigated the role of FDG-PET in T/NK-cell lymphomas. This paper summarizes the current information regarding the potential use of PET/CT in patients with T-cell lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.

    PubMed  CAS  Google Scholar 

  2. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18 F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun. 1999;20:13–20.

    Article  PubMed  CAS  Google Scholar 

  3. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine- 18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889–99.

    Article  PubMed  CAS  Google Scholar 

  4. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47:1643–8.

    PubMed  Google Scholar 

  5. Kwee TC, Kwee RM, Nievelstein RA. Imaging in stagin of malignant lymphoma: a systematic review. Blood. 2008;111:504–16.

    Article  PubMed  CAS  Google Scholar 

  6. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol. 2001;12:825–30.

    Article  PubMed  CAS  Google Scholar 

  7. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2- [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9:1117–22.

    Article  PubMed  CAS  Google Scholar 

  8. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86:266–73.

    PubMed  CAS  Google Scholar 

  9. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81:20–5.

    Article  PubMed  CAS  Google Scholar 

  10. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer. 2004;90:620–5.

    Article  PubMed  CAS  Google Scholar 

  11. Newman JS, Francis JR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-Dglucose: correlation with CT. Radiology. 1994;190:111–6.

    PubMed  CAS  Google Scholar 

  12. Thill R, Neuerburg J, Fabry U, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin. 1997;36:234–9.

    PubMed  CAS  Google Scholar 

  13. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875–6.

    Article  PubMed  CAS  Google Scholar 

  14. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) and a comparison of 18FFDG- PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652–9.

    Article  PubMed  Google Scholar 

  15. • Khong P-L, Pang CBY, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613–21. This article presents interesting data on the role of PET scans in mature T-cell and NK-cell malignancies.

  16. • Berk V, Yildiz R, Akdemir UO, et al. Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules. Utility of 18F-FDG PET in staging. Clin Nucl Med. 2008;33:365–6. This article presents an evaluation of PET scans in rating T-cell disorders.

  17. Kako S, Izutsu K, Ota Y, et al. FDG PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–90.

    Article  PubMed  CAS  Google Scholar 

  18. Suh C, Kang Y-K, Roh J-L, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated exranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783–9.

    Article  PubMed  Google Scholar 

  19. Horwitz SM, Foss F, Goldfarb S, et al. FDG-PET scans as a staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood. 2006;108:679a. abstract 2399.

    Google Scholar 

  20. Karantanis D, Subramanium RM, Peller PJ, et al. The value of [18F] fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8:94–9.

    Article  PubMed  Google Scholar 

  21. Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47:1622–7.

    PubMed  Google Scholar 

  22. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 1994;8:187–91.

    Article  PubMed  CAS  Google Scholar 

  23. Watanabe N, Murakami J, Kameda K, et al. F-18 FDGPET imaging in adult T-cell leukemia lymphoma. Clin Nucl Med. 2008;33:423–5.

    Article  PubMed  Google Scholar 

  24. Shapiro M, Yun M, Junkins-Hopkins JM, et al. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Amer Acad Dermatol. 2002;47:623–8.

    Article  Google Scholar 

  25. Hoffmann M, Vogelsang H, Kletter K, et al. 18F-fluorodeoxy- glucose positron emission tomography (18FFDG- PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52:347–51.

    Article  PubMed  CAS  Google Scholar 

  26. • Kuo PH, McClennan BL, Carlson K, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol. 2008;10:74–81. This article compares PET and CT scans in the evaluation of patients with cutaneous T-cell lymphoma.

    Google Scholar 

  27. Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006;142:577–84.

    Article  PubMed  Google Scholar 

  28. Kumar R, Xiu Y, Zhuang HM, et al. 18F-fluorodeoxyglucose- positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol. 2006;155:357–63.

    Article  PubMed  CAS  Google Scholar 

  29. Kuo PH, Carlson KR, Christensen I, et al. FDG-PET/CT for the evaluation of response to therapy of cutaneous Tcell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imaging Biol. 2008;10:306–14.

    Article  PubMed  Google Scholar 

  30. Gallamini A, Rigaci L, Merli F, et al. Predictive value of positron emission tomography performer after two coureses of standard therapy on treatment out come in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.

    PubMed  Google Scholar 

  31. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.

    Article  PubMed  CAS  Google Scholar 

  32. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-D-glucose positron emission tomography is prognostically superior to International prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Istituto di Ematologia “L. e A. Seràgnoli”, Via Massarenti 9, 40138, Bologna, Italy

    Pier Luigi Zinzani

Authors
  1. Pier Luigi Zinzani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pier Luigi Zinzani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zinzani, P.L. PET in T-Cell Lymphoma. Curr Hematol Malig Rep 6, 241–244 (2011). https://doi.org/10.1007/s11899-011-0098-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-011-0098-6

Keywords

Search

Navigation